Proposals now accepted until September 1, 2020
SLAS Discovery Guest Editors Geoffrey Holdgate (AstraZeneca) and Christian Bergsdorf Ph.D. (Novartis) invite the submission of manuscript proposals (abstracts) that describe the best-practice implementation of biophysical methods in drug discovery for publication in a 2021 special issue. Abstracts will be used to select and invite papers for review and publication consideration.
Drs. Holdgate and Bergsdorf seek high-quality, short- or full-length research reports, reviews and perspectives related to impactful current and developing biophysical methods, biophysical screening and characterization, and related analyses and interpretation of biophysical results. Submissions are welcome from academia, industry, and vendors. Areas of interest include, but are not limited to:
Submit your manuscript proposal before September 1, 2020. Proposals should include your name, contact information, affiliation, a working title and abstract (250-500 words) as an MS Word document.
Invited manuscripts will need to be completed and submitted by December 15, 2020.
All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Discovery Special Issue. Submissions from SLAS members, nonmembers and especially attendees of the Drug Discovery Chemistry’s Fragment-Based Drug Discovery annual meeting, NovAlix Biophysics in Drug Discovery Conference, RSC-BMCS Fragment-based Drug Discovery meeting and ELRIG Drug Discovery are welcomed!
Publication note: After submissions are accepted, they typically publish online ahead-of-print within 30 days and become immediately searchable and citable with a DOI.
Questions? Please e-mail email@example.com or call +1.630.256.7527, ext. 106.